The North America rapid test kit market was valued at US$ 6.86 billion in 2022 and is expected to reach US$ 10.46 billion by 2030; it is estimated to record a CAGR of 5.4% from 2022 to 2030.
Sickle SCAN is a rapid test for the identification of sickle cell anemia with high sensitivity and specificity. Rapid diagnostic tests (RDTs) help diagnose malaria by detecting the presence of malarial parasites in human blood. Where access to high-quality microscopy services is limited, radiological diagnosis techniques are used as an alternative for clinical or microscope-based diagnosis. The COVID-19 pandemic had a significant impact on the rapid test kits market. Nearly all diagnostic tests used real-time PCR for testing people who showed symptoms of SARS-CoV-2 infection.
Rapid test kits are nearly ubiquitous, robust, and reliable. Rapid testing techniques that involve the amplification of specific stretches of DNA for genotyping, cloning, and single nucleotide variation analysis are used in most molecular biology labs. Thus, the increasing incidence of genetic and infectious diseases propels the growth of the rapid test kits market.
Rising Prevalence of Genetic and Infectious Diseases Fuels North America Rapid Test Kit Market
A 2022 report by MJH Life Sciences (US) estimates that 300,000 newborns worldwide are born with sickle cell disease every year. According to the CDC, 1 in 500 African Americans is affected by sickle cell disease. The latest World Malaria Report (WMR) 2022 from the World Health Organization (WHO) states that nearly 247 million new malaria cases were reported in the world in 2021, in comparison to 245 million cases that were logged in 2020. According to the same source, the number of deaths caused due to malaria was 619,000 in 2021.Sickle SCAN is a rapid test for the identification of sickle cell anemia with high sensitivity and specificity. Rapid diagnostic tests (RDTs) help diagnose malaria by detecting the presence of malarial parasites in human blood. Where access to high-quality microscopy services is limited, radiological diagnosis techniques are used as an alternative for clinical or microscope-based diagnosis. The COVID-19 pandemic had a significant impact on the rapid test kits market. Nearly all diagnostic tests used real-time PCR for testing people who showed symptoms of SARS-CoV-2 infection.
Rapid test kits are nearly ubiquitous, robust, and reliable. Rapid testing techniques that involve the amplification of specific stretches of DNA for genotyping, cloning, and single nucleotide variation analysis are used in most molecular biology labs. Thus, the increasing incidence of genetic and infectious diseases propels the growth of the rapid test kits market.
North America Rapid Test Kit Market Overview
The rapid adoption of gene synthesis and editing tools such as CRISPR and PCR in research and therapeutics necessitates assays that are helpful in terms of rapid quantification, alterations, and observation. The US, seeking significant funding from public and private organizations, is expected to invest significantly in advanced research methodologies and is expected to be in the leading position in the rapid test kits market. There was a rapid increase in at-home test use occurred between the SARS-CoV-2 Delta- and Omicron-predominant periods of the pandemic. According to the CDC, in April 2023, more than 70 million test kits were shipped across the US.North America Rapid Test Kit Market Segmentation
The North America rapid test kit market is segmented based on type, product, technology, application, end user, and country. Based on type, the North America rapid test kit market is segmented into rapid antigen testing, rapid antibody testing, and others. The rapid antigen testing segment held the largest market share in 2022.- In terms of product, the North America rapid test kit market is bifurcated into over-the-counter rapid testing kit and professional rapid testing kit. The over-the-counter rapid testing kit segment held a larger market share in 2022.
- By technology, the North America rapid test kit market is segmented into lateral flow assay, solid phase, agglutination, immunospot assay, and cellular component-based. The lateral flow assay segment held the largest market share in 2022.
- Based on application, the North America rapid test kit market is categorized into blood glucose testing, infectious disease testing, pregnancy and fertility, cardiometabolic testing, and others. The blood glucose testing segment held the largest market share in 2022.
- In terms of end user, the North America rapid test kit market is segmented into hospital and clinics, home care, diagnostics centers, and others. The hospital and clinics segment held the largest market share in 2022.
- Based on country, the North America rapid test kit market is segmented into the US, Canada, and Mexico. The US dominated the North America rapid test kit market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. North America Rapid Test Kits Market - Key Industry Dynamics
5. Rapid Test Kits Market - North America Market Analysis
6. North America Rapid Test Kits Market Analysis - by Type
7. North America Rapid Test Kits Market Analysis - by Product
8. North America Rapid Test Kits Market Analysis - by Technology
9. North America Rapid Test Kits Market Analysis - by Application
10. North America Rapid Test Kits Market Analysis - by End User
11. North America Rapid Test Kits Market - Country Analysis
12. Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Becton Dickinson and Co
- ARKRAY Inc
- Fujirebio Europe NV
- bioMerieux SA
- Cepheid
- Meril Life Sciences Pvt Ltd
- QIAGEN NV
- OraSure Technologies Inc
- Guangzhou Wondfo Biotech Co Ltd
- Denka Co Ltd
- Abbott Laboratories
- Trinity Biotech Plc
- SD Biosensor Inc
- Bio-Rad Laboratories Inc
- Hologic Inc
- DiaSorin SpA
- Beckman Coulter Inc
